Story
Celldex Hailed by Guggenheim After Positive Phase III Barzovolimab Data
Summary
Guggenheim has named Celldex Therapeutics a top biotechnology performer following strong Phase III trial results for its chronic spontaneous urticaria drug, barzovolimab, positioning it as a potential best-in-disease treatment.
Celldex Therapeutics (NASDAQ:CLDX) has emerged as a leading stock in Guggenheim's biotechnology sector rankings after the company reported highly positive topline results from two pivotal Phase III studies of its drug, barzovolimab.
Pivotal Trial Success
The investment firm's analysis highlighted the successful trials for barzovolimab in treating chronic spontaneous urticaria (CSU). According to Celldex, this represents the largest pivotal program ever conducted for CSU patients who are refractory to antihistamines, a group with significant unmet medical needs.
Guggenheim noted that results from both doses across both studies demonstrated a complete response that nearly aligned with the firm's bull-case scenario. This strong efficacy positions barzovolimab as a potential best-in-disease therapy for the condition.
Safety Profile and Program Setback
AdGuggenheim's analysis also addressed the drug's safety profile, noting that two cases of Grade 4 anaphylaxis across 2,400 patients represent an incidence rate of 0.08%, which the firm described as much lower than most approved drugs. The report pointed out that the Grade 4 designation was based on investigator discretion rather than an independent adjudication.
However, the positive CSU data contrasts with a recent setback for the same drug in a different indication. Celldex recently announced that its Phase II study of barzovolimab for prurigo nodularis failed to meet its primary endpoints, leading the company to discontinue that specific program.
Market Implications
The successful CSU trials address a significant market opportunity in patients who have not responded to existing treatments. The development has drawn mixed reactions from analysts following the full clinical update, with Morgan Stanley reportedly raising its price target on Celldex while Canaccord lowered its target.
Read next
More on Stocks
Tesla FSD System Frequently Exceeds Speed Limits in Belgian Safety Study
A road-safety advocacy group in Belgium found Tesla's Full Self-Driving system often exceeded speed limits and misinterpreted traffic signs during testing. The report comes as European regulators consider a wider approval for the technology.
FAA Head Says Telecom Errors Preceded Outage That Disrupted 9,500 Flights
The Federal Aviation Administration chief revealed that a switch to a backup system due to circuit errors on Sunday was followed by a contractor accidentally severing the line on Monday, causing widespread East Coast flight delays and cancellations.
Barry Diller Withdraws Acquisition Bid for MGM Resorts, WSJ Reports
Media executive Barry Diller has reportedly ended his pursuit of MGM Resorts International, withdrawing a bid after months of discussions with the casino operator, according to The Wall Street Journal.
Global Debt Hits Record $365 Trillion After $10 Trillion Surge in H1 2026, IIF Reports
Global debt reached a new record of over $365 trillion in the first half of 2026, driven by a $10 trillion increase primarily from emerging markets, according to the Institute of International Finance.